A detailed history of Allspring Global Investments Holdings, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 858,004 shares of EXEL stock, worth $24.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
858,004
Previous 1,137,300 24.56%
Holding current value
$24.7 Million
Previous $25.6 Million 12.87%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$21.96 - $27.6 $6.13 Million - $7.71 Million
-279,296 Reduced 24.56%
858,004 $22.3 Million
Q2 2024

Jul 26, 2024

SELL
$20.34 - $23.73 $2.88 Million - $3.36 Million
-141,610 Reduced 11.07%
1,137,300 $25.6 Million
Q1 2024

Apr 18, 2024

SELL
$20.17 - $23.93 $2.04 Million - $2.42 Million
-101,111 Reduced 7.33%
1,278,910 $30.3 Million
Q4 2023

Jan 25, 2024

SELL
$19.25 - $24.13 $548,586 - $687,656
-28,498 Reduced 2.02%
1,380,021 $33.1 Million
Q3 2023

Oct 27, 2023

BUY
$19.04 - $22.74 $26.8 Million - $32 Million
1,408,519 New
1,408,519 $30.8 Million
Q2 2023

Jul 18, 2023

SELL
$18.17 - $20.48 $3.9 Million - $4.39 Million
-214,472 Reduced 9.67%
2,002,496 $38.3 Million
Q1 2023

Apr 13, 2023

BUY
$16.3 - $19.41 $7.15 Million - $8.52 Million
438,819 Added 24.68%
2,216,968 $43 Million
Q4 2022

Jan 23, 2023

BUY
$14.96 - $17.39 $7.59 Million - $8.83 Million
507,662 Added 39.96%
1,778,149 $0
Q3 2022

Oct 26, 2022

BUY
$15.68 - $22.27 $2.55 Million - $3.63 Million
162,826 Added 14.7%
1,270,487 $19.9 Million
Q2 2022

Jul 25, 2022

SELL
$17.44 - $23.16 $149,931 - $199,106
-8,597 Reduced 0.77%
1,107,661 $23.1 Million
Q1 2022

May 02, 2022

BUY
$17.03 - $22.67 $9.04 Million - $12 Million
530,993 Added 90.73%
1,116,258 $25.3 Million
Q4 2021

Jan 28, 2022

BUY
$15.84 - $21.88 $9.27 Million - $12.8 Million
585,265 New
585,265 $10.7 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $9.25B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.